According to Sun Pharma, the purpose of the strategic investment is to obtain access to the technology for certain compounds and territories while also fostering the development of novel pharmaceutical delivery systems.
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
Sirius JV will be owned 51% by Sirius and 49% by Adani
Marks remarkable acceleration in innovation using AI technology
The acquisition is done through cash consideration, by way of conversion of SAFE (Simple Agreement for Future Equity) investment of US$ 2 Million to Preferred A-1 Shares
Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908
The establishment of the facility demonstrates the company's commitment to delivering differentiated solutions to gynecology and pediatrics challenges
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure
The agreement grants Brinter the distribution rights of GrowInk bioinks in many countries
Softovac Liquifibre expands the Softovac product portfolio and provides a choice for consumers who prefer time-tested Ayurvedic ingredients
Subscribe To Our Newsletter & Stay Updated
